United Therapeutics Corp (UTHR) Reports Q4 EPS of $0.79, Reaffirms FY12, FY13 Guidance
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $538.30 +0.32%
Revenue Growth %: +1.5%
Financial Fact:
Income from continuing operations before income taxes: 239.1M
Today's EPS Names:
JFIN, KEQU, LASE, More
Revenue Growth %: +1.5%
Financial Fact:
Income from continuing operations before income taxes: 239.1M
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
United Therapeutics Corp (NASDAQ: UTHR) reported Q4 EPS of $0.79, $0.08 worse than the analyst estimate of $0.87. Revenue for the quarter came in at $195.2 million versus the consensus estimate of $204.81 million.
United Therapeutics Corp reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics Corp (UTHR) click here.
United Therapeutics Corp reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics Corp (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Robinhood prices $2B convertible notes offering due 2029
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
